de Ávila Machado MA, et al. - Experts compared the efficacy and safety of tofacitinib, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor inhibitors (TNFi), and non-TNF biologics in subjects having RA previously treated with methotrexate. While comparing tofacitinib with non-TNF biologics, differences with respect to hospitalized infections or effectiveness were not seen. Results suggested similar effectiveness rates of tofacitinib and non-TNF biologics. It was noted that DMARD initiators were less effective than non-TNF biologics.